Thats not quite what happened when Eli Lilly dropped Phase 3 data on retatrutide last month and the nuance explains the real story unfolding across the pharmaceutical industry right now
The SOUL cardiovascular outcomes trial (CVOT) demonstrated a 14% relative reduction in risk of MACE in patients treated with Rybelsus 14 mg orally once daily for approximately 5 years compared to those who received placebo
For the primary endpoint of HbA1c reduction, the mean changes from baseline were -1.87%, -1.89%, and -2.07% for the 5 mg, 10 mg, and 15 mg doses, respectively, compared to a +0.04% change for placebo
Informacin de seguridad Riesgos para la salud Prevencin y control de riesgos Pictogramas GHS - Irritacin Tratamiento de emergencia por derrames: Aspire o barra el material y colquelo en un contenedor de eliminacin adecuado
That's why the new changes people are reporting while taking certain GLP-1 medications have become so concerning
doi: 10.1038/s41574-018-0118-x 41 Del PratoSGallwitzBHolstJJMeierJJ
